{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T17:02:17Z","timestamp":1778864537943,"version":"3.51.4"},"reference-count":0,"publisher":"Termedia Sp. z.o.o.","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arch Med Sci"],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>We assessed benefits and harms of sacubitril\/valsartan (S\/V) compared to angiotensin converting enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARB) in patients with heart failure (HF).<\/jats:p><\/jats:sec><jats:sec><jats:title>Material and methods<\/jats:title><jats:p>We systematically searched for randomised controlled trials (RCTs) evaluating S\/V vs ACEI or ARB in acute or chronic HF in August 2021. Primary outcomes were HF hospitalisations, and cardiovascular (CV) mortality; secondary outcomes included all-cause mortality, biomarkers, and renal function.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>We selected 11 RCTs (n=18766) with 2-48 months follow-up. Five RCTs had ACEIs as control, five RCTs had ARBs as control, and one RCT had both ACEI and ARB as control. Compared to ACEI or ARB, S\/V reduced HF hospitalisations by 20% (HR 0.80, 95%CI 0.68-0.94; 3 RCTs; I2=65%; high CoE), CV mortality by 14% (HR 0.86, 95%CI 0.73 to 1.01; 2 RCTs; I2=57%; high CoE) and all-cause mortality by 11% (HR 0.89, 95%CI 0.78-1.00; 3 RCTs; I2=36%; high CoE). S\/V reduced NTproBNP (SMD -0.34, 95%CI -0.52 to -0.16; 3 RCTs; I2=62%), hs-TNT (Ratio of differences 0.84, 95%CI 0.79-0.88; 2 RCTs; I2=0%), and decline in renal function by 33% (HR 0.67, 95%CI 0.39-1.14; 2RCTs; I2=78%; high CoE). S\/V increased hypotension (RR 1.69, 95%CI 1.33-2.15; 9 RCTs; I2=65%; high CoE). Hyperkalaemia and angioedema events were similar. Effects were in the same direction when stratified by type of control (ACEI vs. ARB).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Sacubitril\/valsartan had better clinical, intermediate, and renal outcomes in HF in comparison to ACEI or ARB. There was no difference in angioedema and hyperkalemia events, but more hypotension events.<\/jats:p><\/jats:sec>","DOI":"10.5114\/aoms\/159113","type":"journal-article","created":{"date-parts":[[2023,1,10]],"date-time":"2023-01-10T21:05:16Z","timestamp":1673384716000},"source":"Crossref","is-referenced-by-count":4,"title":["Efficacy and safety of sacubitril\/valsartan in heart failure compared to renin\u2013angiotensin\u2013aldosterone system inhibitors: a systematic review and meta-analysis of randomised controlled trials"],"prefix":"10.5114","author":[{"given":"Adrian","family":"Hernandez","sequence":"first","affiliation":[{"name":"University of Connecticut, United States"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vinay","family":"Pasupuleti","sequence":"additional","affiliation":[{"name":"Lumanity Communications Inc., United States"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nancy","family":"Scarpelli","sequence":"additional","affiliation":[{"name":"University of Connecticut, United States"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jack","family":"Malespini","sequence":"additional","affiliation":[{"name":"University of Connecticut, United States"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maciej","family":"Banach","sequence":"additional","affiliation":[{"name":"Medical University of Lodz, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agata","family":"Bielecka-Dabrowa","sequence":"additional","affiliation":[{"name":"Medical University of Lodz, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3061","published-online":{"date-parts":[[2023,1,10]]},"container-title":["Archives of Medical Science"],"original-title":[],"link":[{"URL":"https:\/\/www.archivesofmedicalscience.com\/pdf-159113-85331","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.archivesofmedicalscience.com\/pdf-159113-85331","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,10]],"date-time":"2023-01-10T21:05:16Z","timestamp":1673384716000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.archivesofmedicalscience.com\/Efficacy-and-safety-of-sacubitril-valsartan-in-heart-failure-compared-to-renin-angiotensin,159113,0,2.html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,10]]},"references-count":0,"alternative-id":["159113"],"URL":"https:\/\/doi.org\/10.5114\/aoms\/159113","relation":{},"ISSN":["1734-1922","1896-9151"],"issn-type":[{"value":"1734-1922","type":"print"},{"value":"1896-9151","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,10]]}}}